We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.68M
3
CELG
Celgene Corp
CELG
+$9.59M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard Inc.
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.4%
2 Financials 0.94%
3 Industrials 0.35%
4 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLDX icon
126
Celldex Therapeutics
CLDX
$3.12B
$458K 0.05%
10,667
HIND
127
Vyome Holdings
HIND
$15.6M
0
AAC
128
DELISTED
AAC Holdings
AAC
$447K 0.05%
45,000
ALDR
129
DELISTED
Alder Biopharmaceuticals
ALDR
$404K 0.04%
33,000
ESPR
130
DELISTED
Esperion Therapeutics
ESPR
$401K 0.04%
8,000
SGRY icon
131
Surgery Partners
SGRY
$1.87B
$321K 0.03%
31,000
BIB icon
132
ProShares Ultra NASDAQ Biotechnology
BIB
$104M
-19,000
Closed -$1.01M
DVA icon
133
DaVita
DVA
$11.7B
-10,000
Closed -$648K
KITE
134
DELISTED
Kite Pharma, Inc.
KITE
-17,000
Closed -$1.76M
WBMD
135
DELISTED
WebMD Health Corp.
WBMD
-7,400
Closed -$434K
CBPO
136
DELISTED
China Biologic Products Holdings, Inc.
CBPO
-36,250
Closed -$4.1M

Similar funds

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings, Inc. in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.